Cyp17 Polymorphisms and Prostate Cancer Outcomes

Journal of Urology - Netherlands
doi 10.1016/s0022-5347(09)62164-9
Full Text
Abstract

Available in full text

Categories
Urology
Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic

2013English

Association Between NAT2 Polymorphisms and Prostate Cancer

Iranian Journal of Cancer Prevention
2017English

Polymorphisms Inside MicroRNAs and MicroRNA Target Sites Predict Clinical Outcomes in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy

Clinical Cancer Research
Cancer ResearchOncology
2010English

Insulin Resistance-Related Gene Polymorphisms and Risk of Prostate Cancer

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2007English

Brachytherapy in Prostate Cancer: Techniques and Clinical Outcomes

Trends in Urology & Men's Health
2018English

A Novel Nonsense Mutation in Androgen Receptor Confers Resistance to CYP17 Inhibitor Treatment in Prostate Cancer

Oncotarget
Oncology
2016English

Polymorphisms inCYP17andCYP3A4and Prostate Cancer in Men of African Descent

Prostate
OncologyUrology
2012English

Living With Early Prostate Cancer: Decisions and Outcomes

2005English

Risk Prediction of Prostate Cancer With Single Nucleotide Polymorphisms (SNPs) and Prostate-Specific Antigen (PSA)

Journal of Urology
Urology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy